Chemotherapy regimens | Group A* (n=89) | Group B† (n=49) | P value |
Paclitaxel liposome + nedaplatin | 27 (30.3%) | 15 (30.6%) | 0.93 |
Paclitaxel liposome + carboplatin | 8 (9.0%) | 4 (8.1%) | |
Docetaxel + nedaplatin | 18 (20.2%) | 8 (16.4%) | |
Docetaxel + carboplatin | 36 (40.5%) | 22 (44.9%) |
*Group A: consolidation chemotherapy group.
†Group B: concurrent chemoradiotherapy alone group.